Analysts Note Medtronic’s Tummy Tuck Surgery Sales Unaffected Globally Amid Weight-Loss Treatment(s) Rush

William Blair writes that Medtronic Plc’s (NYSE:MDT) Q1 FY24 witnessed a remarkable performance cascaded to the bottom line, amplified by improved gross margins due to better pricing discipline and effective control and leverage of operating expenses.

The positive trajectory observed in Q1 underscores Medtronic’s efforts in stabilizing its business operations and delivering results in alignment with, if not exceeding, market expectations.